| Literature DB >> 14578562 |
Punita Kumari Sodhi1, Lalit Verma, John Ratan.
Abstract
Brimonidine is a potential first line therapy for primary open angle glaucoma (OAG) and ocular hypertension (OHT). It is known to cause various ocular and systemic side effects. Being a newer drug, the whole spectrum of its adverse effects is not known. The dermatological side effects caused by brimonidine have rarely been reported before. We present three OAG patients who presented to us with contact dermatitis of periorbital skin and lichen planus of nail following the use of topical brimonidine (0.2% twice a day) for more than six months. These side effects slowly disappeared on discontinuing the drug but reappeared on reintroducing topical formulation. Such side effects from the use of brimonidine have not been reported before.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14578562 DOI: 10.1111/j.1346-8138.2003.tb00461.x
Source DB: PubMed Journal: J Dermatol ISSN: 0385-2407 Impact factor: 4.005